Objectives: Based on this, the central therapeutic effects of thymol were verified in the neurotrophic pathway.
Methods: Female swiss mice were divided into four groups: control, corticosterone (Cort), thymol (Cort + thymol) and fluvoxamine (Cort + Flu). The administration of corticosterone was used to induce depressive symptoms for 23 days. After the treatment, the animals were exposed the behavioural tests, such as forced swimming test, tail suspension test, sucrose preference test, light/dark test, social interaction test, Y-maze test, plus-maze test and hole-board test. The hippocampus was also removed, and BDNF was measured by ELISA and Western blot.
Key findings: As a result, thymol and fluvoxamine were able to reverse the depressive symptoms, as well as to improve the anxious frame. The anhedonic and short-term memory was restored with the treatment. In the neurochemical tests, both thymol and fluvoxamine restored BDNF levels, improving the depressive condition.
Conclusions: This work opens up new investigations aiming at the use of this molecule as a therapeutic alternative for treating depression disorders.
Keywords: BDNF; corticosterone; depression; thymol.
© 2019 Royal Pharmaceutical Society.